Gedeon Richter UK acquires rights to schizophrenia treatment Reagila from Recordati Pharmaceuticals
pharmafile | February 17, 2026 | News story | Manufacturing and Production | Gedeon Richter UK, Neurology
Gedeon Richter UK has announced its acquisition of full marketing and distribution rights to Reagila (cariprazine), a schizophrenia treatment, from Recordati Pharmaceuticals.
The terms of the agreement state that Gedeon Richter UK will acquire rights to UK promotion of Reagila and hold UK Marketing Authorisation.
Reagila is a product of Gedeon Richter’s R&D and is approved to treat schizophrenia in adults. Gedeon Richter UK’s acquisition of the treatment builds on its existing portfolio of treatments for central nervous system conditions. Richter will now market Reagila in the UK via its direct affiliates, adding to the list of countries where the treatment has been marketed.
The transfer will include the move of Joe Durante, previously National Neuroscience Advisor at Recordati, to the same position at Gedeon Richter UK. UK patients who are already being treated with cariprazine will continue to have their treatment distributed by Gedeon Richter.
Schizophrenia is a psychological disorder characterised by symptoms including hallucinations, delusions and emotional symptoms. It is often treated with a combination of medications and therapy.
Remigijus Narauskas, managing director of Gedeon Richter UK, commented on “Richter’s heritage in neuropsychiatry and the pivotal role we played in the development of cariprazine, which was first discovered by Richter scientists in the early 2000s.”
He added: “A strategic decision has been made to bring UK commercialisation of cariprazine to Gedeon Richter UK.”
David Jordan, medical director of Gedeon Richter UK and Ireland, said: “Schizophrenia is a chronic and disabling disorder that imposes a significant burden on patients and their loved ones. We are committed to improving the quality of life for those suffering from this chronic mental health condition.”
Gedeon Richter is an international pharmaceutical and biotechnology company.
